肺腺癌伴EGFR和KIF5B-MET共突变1例并文献复习
Lung adenocarcinoma with EGFR and KIF5B-MET co-mutations:A case report
徐凯文 1董周寰 1朱凤伟 1陈雷 2高杰1
作者信息
- 1. 解放军总医院第一医学中心病理科,北京 100853
- 2. 解放军总医院第一医学中心胸外科,北京 100853
- 折叠
摘要
随着基因检测技术的迅猛发展,通过检测肺癌患者的分子改变以指导临床靶向治疗已成为主流趋势.本文报道1例患者,男,51岁,解放军总医院第一医学中心病理科分子病理诊断实验室检测诊断为肺腺癌,临床TNM分期T1bN0M0,二代测序检测EGFR(L858R)和KIF5B-MET罕见基因融合双突变.患者行视频辅助胸腔镜手术右肺上叶切除+纵隔淋巴结清扫术后未进行靶向治疗和放化疗.随访至今患者预后良好.通过分析临床资料、诊疗过程和疾病转归,探讨了非小细胞肺癌患者新突变形式和相关治疗靶点.早期肺癌根治术治疗效果良好,二代测序对于发现患者罕见突变和寻找治疗靶点有重要意义.
Abstract
With the development of genetic testing technology,it has become a mainstream to detect molecular alterations in lung cancer patients to guide clinical targeted therapy.This article reports a 51 year-old male patient diagnosed as lung adenocarcinoma in the molecular pathology diagnostic laboratory of Department of Pathology of the First Medical Center of Chinese PLA General Hospital,with clinical TNM stage T1bN0M0,and double mutation of rare gene fusion of EGFR(L858R)and KIF5B-MET by second-generation sequencing.The patient underwent video-assisted thoracoscopic surgery(VATS),which involved resection of the upper lobe of the right lung and clearance of the mediastinal lymph nodes.After surgery,no targeted therapy or radiotherapy was performed,and the prognosis was good since the follow-up.By analyzing the clinical data,diagnosis and treatment process and disease regression of the patient,the new mutation forms and related therapeutic targets in non-small cell lung cancer(NSCLC)patients are investigated,suggesting that early radical lung cancer treatment is effective,and second-generation sequencing is important for identifying rare mutations and therapeutic targets.
关键词
肺癌/EGFR突变/KIF5B-MET融合/二代测序/分子病理Key words
lung cancer/EGFR mutation/KIF5B-MET fusion/next-generation sequencing/molecular pathology引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据